Letrozole in Induction of Abortion of Anembryonic Pregnancy

Letrozole Plus Misoprostol Versus Misoprostol Alone in Induction of Abortion of Anembryonic Pregnancy:

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05198050

Enrollment

Registered

2022-01-20

Start date

2022-04-03

Completion date

2022-09-30

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anembryonic Pregnancy

Keywords

Letrozole, misoprostol, induction of abortion

Brief summary

Some studies suggest the prescription of aromatase inhibitors prior to the use of misoprostol for inducing drug abortion. the aim of the study is to compare the effectiveness of various regimens of letrozole combined with misoprostol versus using misoprostol alone in inducing complete abortion in patients with blighted ovum.

Detailed description

Some studies suggest prescription of aromatase inhibitors prior to the use of misoprostol for inducing drug abortion, increases the efficiency of the treatment regimen and also decreases the need for surgical interventions. Some conducted studies have mentioned reinforcing the impact of misoprostol with letrozole, but reaching the ideal dose still needs more studies, so in this study, the investigators will compare the effectiveness of various regimens of letrozole ( 10 mg/d for 3 days or a single dose of 20 mg) combined with misoprostol versus using misoprostol alone in inducing complete abortion in patients with a blighted ovum.

Interventions

DRUGLetrozole tablets

Letrozole is a third-generation non-steroidal aromatase inhibitor

DRUGMisoprostol Tabets

a synthetic prostaglandin medication

DRUGPlacebo tablets

Placebo tables with a similar appearance to letrozole

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE (Subject)

Intervention model description

A randomized controlled trial

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* first trimester of pregnancy * pregnancy duration less than 12 weeks based on LMP. * non-viable fetus (blighted ovum)

Exclusion criteria

* No heart disease, * No asthma * No History of thromboembolism * No History of cancer * No renal failure * No liver diseases * History of allergy to misoprostol or letrozole drugs.

Design outcomes

Primary

Measure	Time frame	Description
Complete abortion	2 days	no emergency or elective curettage was necessary until next menstruation

Secondary

Measure	Time frame	Description
Adverse effects of Letrozole	2 days	hot flushes, drowsiness and nausea.
Induction-to-abortion interval	2 days	the interval between administration of misoprostol)
Adverse effects of Misoprostol	2 days	diarrhea, abdominal cramps, fever and sweating.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026